Aptar Pharma's Preservative-Free Multidose Dispenser Chosen for the First Time for a Prescription Dry Eye Product in the US with RESTASIS MULTIDOSE™

CRYSTAL LAKE, Ill.--()--Aptar Pharma’s innovative and patented preservative-free multidose Ophthalmic Squeeze Dispenser is available for patients in the U.S. prescription market for the first time with Allergan’s RESTASIS MULTIDOSE™ (Cyclosporine Ophthalmic Emulsion) 0.05%.

This approval and launch makes the Aptar Pharma Ophthalmic Squeeze Dispenser the very first, and only, U.S. FDA-approved multidose delivery system to handle prescription eye treatment formulations without any preservatives.

Meeting the needs of patients

Aptar Pharma is working closely with eye care specialist Allergan to improve patient safety, achieve dosing accuracy and maintain product integrity.

Dry eye patients use eye drops on a regular basis, and often for the rest of their lives. It is well-proven that preserved medications may cause unpleasant and sometimes serious side effects.

FDA approval

The increasing number of patients experiencing eye irritation or allergic reactions with preserved formulations appreciate the fact that preservatives can be removed from eye care medications with Aptar Pharma’s Ophthalmic Squeeze Dispenser system. RESTASIS® and RESTASIS MULTIDOSE™ are FDA-approved prescription treatments to help patients suffering from Chronic Dry Eye to make more of their own tears.

Making ophthalmic solutions easier and safer to deliver

Aptar Pharma’s Ophthalmic Squeeze Dispenser system is the result of more than 10 years of development and experience in the delivery of preservative-free ophthalmic solutions. Patients and consumers in Europe, Latin America and Asia have benefited from this technology since 2012 with more than 100 commercial references now available on the market.

RESTASIS® is not an artificial tear. It is a prescription medicine that helps increase the eyes' natural ability to produce tears.

“Our Ophthalmic Squeeze Dispenser technology has been a great success for our customers,” explained Salim Haffar, President, Aptar Pharma. “The proven and unrivalled microbiological safety, combined with a precise and reproducible drop ejection allows pharmaceutical customers worldwide to enter into discussions with regulatory agencies such as the FDA.” Mr. Haffar also points out the user-friendliness of the system, “The ergonomic and pocket-size design and the intuitiveness of a squeezable container with a low actuation force certainly contribute to the high levels of acceptance among patients and consumers around the world.”

Staying ahead of the market

Aptar Pharma's Ophthalmic Squeeze Dispenser provides a unique competitive advantage by addressing the global trend towards patient-friendly, cost-effective and preservative-free multidose dispensers.

About Aptar Pharma

Aptar Pharma is part of AptarGroup, Inc. (NYSE: ATR), a leading global supplier of a broad range of innovative dispensing and sealing solutions for the beauty, personal care, home care, prescription drug, consumer health care, injectables, food and beverage markets. AptarGroup is headquartered in Crystal Lake, Illinois, with manufacturing facilities in North America, Europe, Asia and South America. For more information, visit www.aptar.com.

This press release contains forward-looking statements. Words such as “expects,” “anticipates,” “believes,” “estimates,” “future” and other similar expressions or future or conditional verbs such as “will,” “should,” “would” and “could” are intended to identify such forward-looking statements. Forward-looking statements are made pursuant to the safe harbor provisions of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and are based on our beliefs as well as assumptions made by and information currently available to us. Accordingly, our actual results may differ materially from those expressed or implied in such forward-looking statements due to known or unknown risks and uncertainties that exist in our operations and business environment. Additionally, forward-looking statements include statements that do not relate solely to historical facts, such as statements which identify uncertainties or trends, discuss the possible future effects of current known trends or uncertainties or which indicate that the future effects of known trends or uncertainties cannot be predicted, guaranteed or assured. For additional information on these and other risks and uncertainties, please see our filings with the Securities and Exchange Commission, including the discussion under “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” in our Form 10-Ks and Form 10-Qs. We undertake no obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise.

Contacts

Media Contact:
Carolyn Penot
Aptar Pharma
+33 1 39 17 20 38
carolyn.penot@aptar.com
or
Investor Relations Contact:
Matthew DellaMaria
AptarGroup, Inc.
815 479 5530
matt.dellamaria@aptar.com

Contacts

Media Contact:
Carolyn Penot
Aptar Pharma
+33 1 39 17 20 38
carolyn.penot@aptar.com
or
Investor Relations Contact:
Matthew DellaMaria
AptarGroup, Inc.
815 479 5530
matt.dellamaria@aptar.com